Kestra Medical Technologies (KMTS) Common Equity (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of Common Equity data on file, last reported at $259.7 million in Q2 2026.

• On a quarterly basis, Common Equity rose 26.41% year-over-year to $259.7 million in Q2 2026; TTM through Apr 2026 was $259.7 million, a 26.41% increase from a year earlier, with the FY2026 full-year figure at $259.7 million, up 26.41% from the prior year.
• Common Equity for Q2 2026 stood at $259.7 million, down from $288.0 million in the prior quarter.
• Over the last five years, Common Equity for KMTS reached as high as $288.0 million in Q1 2026 and fell as low as -$384.2 million in Q1 2024.
• Historically, Common Equity has averaged -$20.3 million across 3 years, with a median of -$22.6 million in 2024.
• On a YoY basis, Common Equity climbed as much as 211.67% in 2026 and fell as far as 26.41% in 2026.
• Year by year, Common Equity stood at -$236.5 million in 2024, then jumped by 169.37% to $164.1 million in 2025, then jumped by 58.25% to $259.7 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $259.7 million in Q2 2026, $288.0 million in Q1 2026, and $164.1 million in Q4 2025.